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Opioids are prescribed to manage moderate to severe pain and can be used with older 
adults; however, they may lead to several adverse effects, including cognitive impairment. 
Objective 
To identify, appraise and synthesise evidence on i) the impact of opioids on cognition in 
older adults with cancer/chronic non-cancer pain, and ii) screening tools/neuropsychological 
assessments used to detect opioid-induced cognitive impairment. 
Methods 
A systematic literature review following the Preferred Reporting Items for Systematic 
Review and Meta-Analysis Protocols (PROSPERO Registration CRD42018092943). MEDLINE, 
EMBASE, PsycINFO, CINAHL, Cochrane Library and Web of Science were searched up to 
December 2018. Randomised controlled trials, quasi-experimental studies and observational 
studies of adults aged ≥65 with cancer/chronic non-cancer pain taking opioids were 
included. A narrative synthesis was conducted. 
Results  
From 4,036 records, 10 met inclusion criteria. Five studies used one screening tool and five 
used a range of neuropsychological assessments; assessing 14 cognitive domains. Most 
studies demonstrated no effect of opioid use on cognitive domains, whilst four studies 
showed mixed effects. In particular, attention, language, orientation, psychomotor function 
and verbal working/delayed episodic memory were worsened. Changes to cognitive 
function were predominantly observed in studies with higher mean doses of opioids 
(120mg–190.7mg oral morphine equivalent daily dose). 
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Conclusion 
Both improvements and impairments to cognition were observed in studies with higher 
mean opioid doses. In clinical practice, a brief screening tool assessing attention, language, 
orientation, psychomotor function, and verbal working/delayed episodic memory, may be 
beneficial to detect worsening cognition in older adults with chronic pain using opioids.  
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Chronic pain is a common problem for older adults (≥65 years old), affecting at least 50% in 
the community and 80% in care homes (1, 2). Persistent pain, often moderate to severe 
intensity, in older adults is frequenty attributed to cancer and chronic non-cancer conditions 
(2-6). Pain can have a pronounced impact on older adults’ independence, social 
engagement, ability to self-care and quality of life (7-10). Yet, it is often under assessed and 
poorly managed in this group (1).  
Opioids are used to manage moderate to severe pain (11) and can be used with older adults 
when they have pain despite other treatments (2, 12). Short-term opioid use has some 
benefit in older adults with chronic non-cancer pain (13, 14). On the other hand, studies on 
the safety and efficacy of the long-term use of opioids in older adults are limited (13-16). 
Evidence suggests that it is unlikely to benefit and may be harmful to those with chronic 
non-cancer pain (15, 17, 18). Effective opioid therapy is dependent on the balance between 
analgesic effectiveness and adverse effects (19). Opioid use can lead to a number of adverse 
effects that impact gastrointestinal, neurological, cardiovascular, pulmonary, urological, 
endocrinological and immune systems; including cognitive impairment (20-25). Although 
these adverse effects are common for all age groups, older adults are at greater risk due to 
comorbidities and polypharmacy (20). In particular, older adults can experience high 
medication burden and risk of drug interactions (9, 26-28). Developing our understanding of 
opioid-related risks in older adults is necessary (29-31), including how we can effectively 
screen for opioid-related issues (2, 30).  
Opioid-induced cognitive impairment can lead to a reduced attention span, disorientation 
regarding time, restlessness, agitation, hallucinations and delirium (32). All of which can 
have a pronounced impact on older adults’ and their carers’ quality of life (32). Concerns 
about these issues can also affect healthcare professionals’ initiation of opioid therapy (33). 
Opioid use and its impact on cognitive function in older adults is understudied. The evidence 
base largely focusses on adult cancer and chronic non-cancer populations, without focus to 
older adults (34-38). Previous systematic reviews of the evidence on older adults have 
focussed on postoperative cognitive impairment (39) or opioids for the management of 
chronic non-cancer pain (40). Understanding the relationship between cognition, opioids 
and pain management in older adults’ is important in enhancing knowledge of healthcare 
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professionals to guide clinical practice, as well as improving patients and carers 
understanding of opioids (41, 42). Additionally, systematic identification and assessment of 
cognitive impairment could be useful in guiding opioid therapy. However, there is little 
consensus on which tools and assessments are effective in identifying cognitive impairment 
and which cognitive domains are impacted by opioids (34, 43, 44). 
Therefore, the aim of this systematic review was to identify, appraise and synthesise the: 
i) Evidence on the impact of opioids on cognition in older adults with cancer and 
chronic non-cancer pain.  
ii) Screening and assessment tools that have been used to detect and assess opioid-
induced cognitive impairment, and to discuss their usefulness for identifying 
cognitive issues in older adults. 
 
Methods 
The protocol for this systematic review was prepared according to Preferred Reporting 
Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) (45, 46) and registered 
with PROSPERO (CRD42018092943) prior to screening and data extraction (47). This 
systematic review was reported in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta Analyses (PRISMA) guidance (48). 
 
Search strategy 
MEDLINE, EMBASE and PsycINFO (via Ovid), CINAHL Plus (now CINAHL Complete, via 
EBSCO), Cochrane Central Register of Controlled Trials in the Cochrane Library (via Wiley), 
Web of Science (Science Citation Index Expanded, Social Sciences Citation Index, Arts & 
Humanities Citation Index, Emerging Sources Citation Index, Conference Proceedings 
Citation Index – Science and Conference Proceedings Citation Index – Social Science & 
Humanities), ProQuest and OpenGrey databases were searched from inception to 
December 2018. Search terms were identified from existing reviews. Free text terms for 
searching titles, abstracts and key words were combined with database-specific MeSH terms 
that reflect the following aspects; [opioids] AND [cognition] AND [older adult population] 
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(see Appendix 1: Example of the full search strategy). No electronic limits were applied to 
database searches. 
The reference lists of relevant systematic reviews and first author’s EndNote library were 
screened to identify further studies that may not have been identified in the database 
searches. Where full-texts were not available or lacked information to confirm eligibility, 
authors were contacted. 
 
Study selection 
The studies returned from the search were imported into EndNote X8 and duplicates were 
removed. Titles and abstracts were screened for inclusion by two authors (SP and MD) 
independently in duplicate. For articles that potentially met inclusion criteria on title and 
abstract, SP and MD then assessed full-texts for eligibility. Disagreements between the two 
authors at all stages were resolved through discussion with a third reviewer (JB).   
Table 1 lists the criteria for including studies. For the purpose of this review, older adults in 
this systematic review were defined by the chronological age of ≥65, as commonly adopted 
by most developed countries to describe older adults (49, 50). 
 
Data extraction and analysis 
SP and MD extracted data to electronic data extraction forms, independently in duplicate. 
Data extraction forms were crosschecked for accuracy and missing data. Data collected 
included general information (author and year, type of publication, country of origin, source 
of funding and conflicts of interest), study characteristics (aim, study design, inclusion and 
exclusion criteria, recruitment procedures and study duration), participant characteristics 
(number of participants, source and setting of population, age, gender, disease 
characteristics, comorbidities and concurrent medications), how cognitive impairment was 
assessed (screening tools and/or neuropsychological assessments) and other outcomes 
collected, details of opioid treatment (type, dose, route of administration and length of use), 
statistical analyses used, the effect of opioids on cognition, limitations, and conclusions.  
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Quality was independently assessed by two authors (SP and MD) using the Standard Quality 
Assessment Criteria for Evaluating Primary Research Papers from a Variety of Fields 
(QualSyst) 14-item checklist for quantitative studies (51). A summary score is calculated for 
each paper by dividing the total sum by total possible sum (51). In this systematic review, 
the reviewers used the calculated score to define the quality of papers as strong (score 
of >0.80), good (0.71–0.79), adequate (0.50–0.70) or poor (<0.50) and did not exclude on 
account of poor quality, in line with other systematic reviews (52, 53).  
A narrative synthesis was used, guided by Popay and colleagues (54). A theory of how, why 
and for whom the intervention worked was not developed for this systematic review as 
previous reviews of a similar nature found variable effects on cognition after opioid use. An 
exploratory approach was used, with study design/methods, sample size, diagnosis, 
tools/assessments used, and opioid dose and length of use identified as factors to consider 
in the synthesis. Secondly, tabulation was used to develop a preliminary synthesis of 
included studies to aid interpretation of patterns across studies. Data regarding dose was 
transformed into oral morphine equivalent daily dose (MEDD) to enable dose comparison 
between studies. Thirdly, outcomes of tools and assessments were mapped against 
cognitive domains assessed to analyse similarities and differences across studies. 
Additionally, the cognitive outcomes were mapped against previously identified cognitive 
domains affected by chronic opioid use (namely cognitive flexibility, cognitive impulsivity 
and verbal working memory) (43), as well as ‘additional’ domains captured by the screening 
tool and neuropsychological assessments of included studies. Lastly, a critical reflection of 




A total 4,036 unique records were identified. Of these, 57 full-texts were screened and 10 
were found eligible for inclusion (see Figure 1: PRISMA flowchart). For a summary of 





Included studies were conducted in the United Kingdom (N=3), Italy (N=3), United States of 
America (N=3) and Finland (N=1). All studies were published in English. The studies 
comprised of three randomised controlled trials (55-57), six observational (58-63) and one 
quasi-experimental design (64). Four studies adopted the use of comparison groups to: (i) 
determine the efficacy of opioid use versus conventional therapy (55), (ii) assess the 
difference between central nervous system (CNS) medication users and controls (with 
opioid subgroup analyses) (60), (iii) determine the difference between opioid users and non-
opioid users (61) and (iv) investigate whether opioids or the disease itself had an impact on 
cognition (64). 
 
Population and settings 
A total of 1,087 participants were included in the 10 studies. Changes to cognition from 
opioid use were explored by two studies in older adults with cancer pain (63, 64), six studies 
in older adults with chronic non-cancer pain (55, 57-59, 61, 62) and two studies that 
included both (56, 60). Across nine of the ten included studies (55-59, 61-64), 44 
participants had cancer pain, 462 participants had chronic non-cancer pain (predominantly 
osteoarthritis and postherpetic neuralgia) and 16 participants were healthy controls. In 
Puustinen et al. (2011), diagnoses were only available for 156 CNS medication users and 243 
CNS medication non-users of the 565 recruited. This included both cancer and non-cancer 
diagnoses. However, participants who were taking opioids only had diagnoses of painful 
arthritic diseases (60).   
Study settings varied; two were conducted at a hospice (with one including both inpatients 
and outpatients) (63, 64). The other studies were conducted within a municipality (i.e. single 
urban area) (60) as well as a multi-centre ambulatory services (58), nursing home (55), 
palliative care unit (inpatient and outpatient) (56), pain treatment centre (62), an older pain 
management program (61) and rehabilitation centre (59). One study did not clearly specify a 




Tools and assessments used to identify changes to cognition   
Table 3 summarises the screening tool and neuropsychological tests used to identify and 
assess changes to cognition from opioid use, including a description, cognitive domains 
assessed and outcomes of the tests.   
 
Type and combination 
One screening tool and twenty-one neuropsychological assessments were used to identify 
changes to cognition from opioid use. Five studies (55, 58-60, 62) adopted the use of a 
screening tool (i.e. the Mini-mental State Exam; MMSE) in isolation and five studies (56, 57, 
61, 63, 64) used a combination of neuropsychological tests. The MMSE was the most used 
instrument across all studies. Studies using neuropsychological assessments to assess 
cognition adopted different combinations of assessments. Clemons et al. (1996) stated that 
the National Adult Reading Test was resistant to the effects of drugs, whilst the Stroop-
Colour Word Test was likely to give an indication of changes to cognition from opioid use 
(64). Kamboj and colleagues (2005) also acknowledged that the Prose Recall Test would be 
sensitive to opioid-induced recall impairments (56). The Cognitive Drug Research (CDR) 
computerised assessment used by McNamara and colleagues (63) was developed to assess 
effects from novel compounds on cognitive function, in both volunteers and patients in 
clinical drug development (65). Other studies did not discuss the tools/assessments 
relevance to detect opioid-induced cognitive impairment.  
 
Administration  
The timing of screening tool and neuropsychological assessment administration varied 
across studies. Most studies provided limited description around when tests were 
administered (80%, n=8) (55, 57-63). Those that provided more detailed information about 
administration generally provided timings in terms of hours or minutes after taking opioids 
to ensure that opioid plasma levels were at their peak and/or that the timing of tests 
remained consistent at each visit (56, 64). Nine of the ten studies measured cognition at 
baseline but follow-up periods ranged from 2 weeks to 52 weeks. Karp and colleagues 
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(2006) conducted neuropsychological assessments within 2 weeks of recruitment to 
minimise effects of newly prescribed treatments on the assessment outcomes (61).   
 
Cognitive domains  
Fourteen cognitive domains were covered by the tool and assessments (see Table 3). 
Cognitive domains captured include attention, cognitive flexibility (including verbal and non-
verbal fluency), concentration, language, memory (both short-term and long-term, as well 
as speed of memory retrieval), orientation, pre-morbid IQ, psychomotor function, 
psychomotor sedation, psychomotor speed, reaction speed and reasoning. 
 
Changes to cognition 
There were mixed effects of opioids on cognition in older adults with cancer and chronic 
non-cancer pain (see Table 3). Four studies (112 participants taking opioids) (56, 60, 61, 63), 
demonstrated a change in cognition from opioid use when comparing the effects of 
morphine with a matched placebo (56), switching opioids (63) or between those who 
received opioid treatment and a control group comparison (60, 61). Control group 
comparisons consisted of non-opioid users (N=27) (61), and those using no CNS medication 
(N=384) and non-users of corresponding medications (N=556) (60). In six studies (233 
participants taking opioids), no changes to cognition were observed from baseline to follow-
up between groups (55, 64) or in a cohort of participants (57-59, 62). Sixteen healthy 
controls and six advanced cancer patients not taking opioids (64), and 33 participants 
receiving conventional therapy (i.e. acetaminophen, non-steroidal anti-inflammatory drugs, 
COX-2-Inhibitor) not taking opioids (55) were used as control group comparisons. In four of 
the ten included studies, exploring changes to cognition from opioid use was the primary 




Mapping cognitive domains and outcomes to opioid use in older adults 
As discussed above, studies assessed cognitive function using either a screening tool in 
isolation or a combination of neuropsychological assessments covering 14 cognitive 
domains. The screening tools and neuropsychological assessments used have been mapped 
against these different cognitive domains (see Figure 2). Of the three cognitive domains 
identified by Baldacchino and colleagues (43), the screening tool and neuropsychological 
tests of included studies all captured verbal working memory, whilst none captured 
cognitive impulsivity. Cognitive flexibility was captured by three studies (56, 61, 64). Delayed 
recall/long-term memory was the most common ‘additional’ domain covered by included 
studies, followed by attention, language, orientation, concentration, psychomotor function, 
psychomotor speed, memory retrieval speed, pre-morbid IQ, psychomotor sedation, 
reaction speed and reasoning.  
 
Opioid treatment and concurrent medications 
Opioids used varied across studies (see Table 4). Six studies (56-59, 63, 64) examined the 
use of one opioid only (including buprenorphine, fentanyl, morphine and oxycodone).  
Three studies (55, 60, 62) used more than one opioid (including: codeine, 
dextromethorphan, dextropropoxyphene, ethylmorphine, hydromorphone, morphine, 
methadone and oxycodone). Of which, two studies compared differences between drugs; 
including opioids in comparison to antidepressants (57) and between different opioids 
(oxycodone and codeine) (55). Whilst, one study included participants taking one of four 
opioids without comparison (62). Oral administration of opioids was most common, 
followed by transdermal patch and syringe driver. Two studies did not report route of 
administration (57, 60). Karp and colleagues (2006) did not provide detail around the type(s) 
of opioids used or route of administration (61). 
MEDD across all studies ranged from 11.5mg to 190.7mg, with two studies not accounting 
for dose (60, 61). The length of use also varied from approximately 7 days to 72 weeks, with 
one study not accounting for length of use (61). In studies that demonstrated no difference 
to cognition, mean MEDD daily dose ranged from 11.5 to 104.29mg (55, 57-59, 62, 64), 
excluding the 13 participants that were provided with 15mg methadone (150mg MEDD) due 
to adverse effects from morphine (57). In studies that demonstrated a change to cognition, 
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mean MEDD were 190.7mg over an 11.7 day study period (56), 120mg – 240mg over a 14-
day study period (63) and dose not taken into account when comparing baseline with a 7.6 
year follow-up (60) or between opioid users versus non-opioid users, without consideration 
to dose or length of use (61). Pain relief was achieved at low daily doses of opioids in a 
number of studies without detriment to cognition (55, 57-59). Opioid switching also 
demonstrated improvements to patients’ global assessment of wellbeing that were deemed 
clinically significant (63). One study found that pain worsened along with general wellbeing, 
mood and concentration (64).  
The majority of studies provided some description around the use of multiple concurrent 
medications. Three studies reported that pain medications previously taken by patients 
were discontinued before study commencement (55, 57, 58). However, Gianni et al. (2011) 
specified that medications were only stopped if they lacked efficacy (58). Corsinovi et al. 
(2009) acknowledged that concurrent medications were taken at stable doses three weeks 
prior to the study and continued at stable doses (55). Other studies detailed that rescue 
medication was provided for breakthrough pain but the authors did not clearly specify if any 
other medications were taken (58, 63). Three reported the use of concurrent medications 
taken by participants at the time of testing (56, 62, 64), including opioids (64). Puustinen et 
al. (2011) aimed to capture the use of any CNS medication but provided different subgroup 
analyses (60). Two studies did not clearly report whether concurrent medications were 
taken (59, 61).  
 
Risk of bias and reporting quality 
The mean quality score for included papers was 0.77. There were three adequate-quality 
papers (61, 62, 64), two good-quality papers (58, 63) and five strong-quality papers (55-57, 
59, 60). The randomised controlled trials demonstrated consistently high quality (strong; 
0.82–0.93). Observational studies varied in quality, ranging from adequate to strong (0.55–
0.91). The quasi-experimental study was adequate in quality (0.55). Two randomised 
controlled trials reduced chances of selection, performance and detection bias by using 
double-blind, placebo-controlled, randomised approaches (56, 57). Although, one did not 
provide detailed information around randomisation to treatment order and allocation 
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concealment (56). A single-blind approach lacked detail around random sequence 
generation and allocation concealment. However, chances of performance and detection 
bias were reduced by blinding the researchers to the intervention participants received (55). 
Other included studies may be susceptible to selection, performance and detection bias due 
to the absence of randomisation and blinding.  All studies, where relevant, described 
attrition and exclusion from the analysis. Subject selection and sampling frames were not 
well-reported across most studies, along with power calculations to ensure whether the 




This systematic review builds on previous reviews (34-37, 40) by focussing attention to the 
cognitive effects of opioids in older adults with cancer and chronic non-cancer pain. The 
current review also aimed to ascertain the screening and assessment tools used to identify 
changes to cognition from opioid use in this population. This complements recent 
systematic reviews and meta-analyses exploring the neuropsychological consequences of 
opioid use in adults with a chronicity of and/or dependent on opioid use (43) and long-term 
opioid use in adults with chronic non-cancer pain (44).  
 
Opioid-induced cognitive impairment in older adults with cancer and chronic non-cancer 
pain  
Mirroring previous systematic reviews on the cognitive effects of opioid use in adults with 
malignant and non-malignant pain (34-36), the current review found varied effects on 
cognition from opioid use, with six studies demonstrating no change to cognition from 
opioid use. Drawing together the findings from adult cancer populations (36) and chronic 
non-cancer populations (35), an updated review indicated that there was either no 
difference or worsening cognition in adult cancer patients and no difference or an 
improvement in cognition in chronic non-cancer populations (34). In the current review, a 
non-comparative study exploring domains of cognitive function in an older adult population 
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with cancer found that domains did not change (i.e. concentration, quality of secondary 
memory and psychomotor function) or improved (speed of memory retrieval and verbal 
working memory), although numbers were small (63). In another study with a 
predominantly cancer population, changes to cognitive domains were either not present 
(i.e. psychomotor sedation or verbal working memory), improved (i.e. cognitive flexibility), 
worsened (i.e. attention) or improved then worsened (i.e. psychomotor function) across the 
different neuropsychological assessments used (56), although again, the sample was small. 
Whilst in a study that explored cognitive changes from long-term opioid use in chronic non-
cancer patients (i.e. patients with painful arthritic diseases) via a subgroup analysis, there 
was a decline in cognitive function (60). However, there was also very few participants. Karp 
and colleagues (2006) found that opioid users experienced more difficulty with unprompted 
memory compared to opioid users, in those with non-malignant pain (61). Nevertheless, the 
sample size and reporting around opioid use were limited. These findings contrast with 
previous reviews, with improvements to cognition detected in cancer populations and the 
decline of cognition in a chronic non-cancer population. However, methodological 
limitations, small sample sizes and variation in study design pose challenges to drawing 
definite conclusions from the included studies.  
Dose increase was associated with impaired cognition in a previous systematic review (34). 
There is no definitive definition of ‘high dose’ in scientific literature (66); UK guidance states 
that the risk of harm increases at doses above 120mg/day without increased benefit (67). 
Changes to cognition in the current review were mostly observed in studies that adopted 
the use of higher mean opioid doses (i.e. 120mg – 190.7mg MEDD) (56, 63). However, 
Puustinen and colleagues (2011) demonstrated changes to cognition from long-term use of 
opioids, although dose was not taken into account (60). Karp and colleagues (2006) also 
found that unprompted memory was impaired in those who used opioids compared to 
those that did not, without taking dose into consideration (61). A number of studies found 
that low doses of opioids were a valid treatment for moderate to severe chronic pain 
without any associated cognitive impairment (55, 57-59, 62). Although, some studies 
considered to have a low mean dose demonstrated some wide ranges in dose, including 
higher doses (57, 58, 62). Transient improvements to short-term memory and memory 
retrieval speed were also observed after switching from morphine to fentanyl (63). Potential 
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benefits of opioid rotation and opioid switching (68) and the usefulness of fentanyl in 
comparison to morphine (69) were also recognised in excluded studies. However, a multi-
national study on the prevalence and predictors of cognitive dysfunction in adult cancer 
patient demonstrated no difference in cognitive effects between three commonly used 
opioids (fentanyl, morphine, and oxycodone) (70). Although, this study used the MMSE, 
which may not have been sensitive enough to capture subtle differences to cognition. 
Overall, the type of opioids assessed and the doses used across studies varied greatly.  
The previous reviews commented on the methodological weaknesses of studies assessing 
cognitive function in cancer and chronic non-cancer populations (34, 35, 71). The 
weaknesses identified were the use of non-randomised and non-controlled study designs, 
lack of suitable control groups as well as issues around the cognitive effects of pain itself, 
polypharmacy, and other confounders impacting on cognitive outcomes. These issues were 
also recognised within the current review. Studies that adopt a controlled design are 
thought to be of the highest quality (34). This review did not restrict by controlled design or 
study quality as there is limited evidence in this population and we aimed to be inclusive of 
all possible studies. Kendall et al. (2009) highlighted that changes to cognition varied 
between study designs (35). They found no difference to cognition or an improvement in 
RCTs and non-controlled comparative designs and no difference or worsened cognition in 
observational studies. Due to the limited number of included studies in this review and the 
small number of studies that detected a change in cognition, as well as the variety of study 
designs adopted, it was not possible to determine the role of study design in patterns of 
changes to cognition from opioid use. There are also challenges around the appropriateness 
of study design in this older adult population, such as long-term exposure to harmful effects 
of medications (60, 72, 73).   
Impaired cognition is frequently associated with the pain or disease experience (74). The 
use of an appropriate control group is considered important as the use of healthy 
volunteers does not account for the effects of pain or the disease itself (34). An ideal control 
group would include older adults eligible for opioid therapy but not receiving the treatment 
(34). The prolonged use of a placebo or not providing suitable treatment could pose ethical 
issues but such methods can be beneficial if they adopt sound methodological 
considerations (56, 72, 73). One included study used older adults with advanced cancer not 
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taking opioids and healthy volunteers as control groups to determine the impact of opioids 
and the disease itself on cognition (64). However, the reporting of group differences in study 
outcomes were vague and differed between the results and discussion sections of the 
paper; making it challenging to interpret the impact of the disease itself and from the use of 
opioids. The control groups in the other studies consisted of conventional therapies without 
use of opioids (55), those not taking CNS medications or non-users of corresponding 
medications (60) and older adults not taking opioids (and unclear if they are eligible for 
opioid therapy) (61). Therefore, the control groups adopted in other studies did not best 
reflect controlling for appropriate risk factors in the context of opioid-induced cognition. 
Other included studies did not adopt a control group, although, two studies used 
participants as their own controls in cross-over designs (56, 57).  
Older adults commonly take several concurrent medications (27). Older adults’ cognition is 
susceptible to polypharmacy and anticholinergic burden from the use of multiple 
medications (75, 76). A longitudinal cohort study evaluating the combined use of multiple 
CNS medications (including opioids) in healthy older adults, excluded from this review, 
indicated that the combined use of CNS medications, particularly at high doses, were 
associated with cognitive decline in healthy older adults (77). We acknowledge that 
medications for a number of medical conditions may also impact on cognition. The cognitive 
effects of opioids from included studies are difficult to determine due to differences in or 
lack of controlling for the use of multiple medications in a number of studies (55-57, 60, 61, 
63, 64), as well as unclear/poor reporting (58, 59, 61). This may explain some of the 
variability in the cognitive outcomes of included studies. By controlling for medications prior 
to study commencement or during, a better understanding of baseline cognition and opioid 
impact can be gained. Other confounding factors, such as degenerative cognitive 
impairment associated with age, should also be considered. Most included studies had signs 
of severe cognitive impairment or dementia (usually assessed by mini-mental state 
examination (MMSE) score) as an exclusion criterion (55-62).  
More understanding around the effect of opioids on cognition in older adults with cancer 
and chronic non-cancer pain is still needed. Currently, there is a small number of studies 
available. The limitations of current evidence, due to the heterogeneity of results and 
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methodological approach, suggest that we need a more standardised approach, with clearer 
reporting.  
 
Screening tools, neuropsychological assessments and cognitive domains 
There are a wide variety of screening tools and neuropsychological assessments available 
but there is little consensus around a standardised approach to identifying and assessing 
changes to cognition from opioid use (34, 35, 71). In particular, there is limited 
understanding of which tools and assessments may distinguish clinically meaningful changes 
to cognition in older adults with cancer and chronic non-cancer pain. Determining which 
tool(s) and/or assessment(s) are appropriate in this population could provide an accurate 
way to detect changes to cognition over time and inform adjustments to treatment (35, 64).  
The MMSE was the only screening tool identified and was predominantly used across 
included studies. The MMSE was designed for use with patients with dementia and is 
commonly used to assess cognitive function (78, 79). Despite wide acknowledgement in the 
literature that the MMSE lacks sensitivity to detect minor changes to cognition, it is still 
predominantly used as reasonably quick to administer and engrained in clinical practice (80-
83). A significant association between cognitive decline (including attention, language, 
orientation and both short- and long-term memory) and opioid used was demonstrated in 
an observational longitudinal study included in the current review using the MMSE (60). 
However, the small number of participants using opioids and issues with adjusting for some 
risk factors (e.g. alcohol use) limits the interpretation and generalisability of these findings 
to other elderly populations. A large longitudinal study, using self-reports of cognition, 
explored the relationship between opioids on clinical outcomes for patients receiving 
palliative care, it found that opioid use was not related to worsened cognition in an adjusted 
analysis (84). Although, the authors acknowledged that the low cognitive symptom scores 
could have been due to the exclusion of low MMSE scores (i.e. ≤24) and that the included 
sample represented a group with lower risk of cognitive deterioration (84). Other included 
studies in this review that adopted the MMSE did not detect a difference. Evidence supports 
the use of other, more nuanced, brief screening tools subsequently developed to detect 
mild changes to cognition in older adults compared to the MMSE (79, 85, 86). The use of 
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alternative screening tools has been recognised in substance misuse research, including 
opioid misuse (87-89).  
Neuropsychological effects from opioid use are well-documented (34, 35, 42-44, 71). 
Neuropsychological assessments can detect subtle changes to cognition from opioid use 
(90). However, we do not know if performance on neuropsychological tests relate to 
clinically relevant effects or recommendations (42, 43, 90). The single measure focus of 
neuropsychological tests (e.g. attention) is problematic in drawing conclusions around 
cognitive impairment from opioid use (42), as multiple domains appear to be affected. The 
included studies that adopted neuropsychological tests used multiple assessments to assess 
different cognitive domains. The Incidental Learning Tests (i.e. free recall), Prose Recall Test, 
Trail Making Task and subtests of the CDR computerised assessment detected changes to 
cognition (56, 61, 63). The use of multiple assessments may be challenging in clinical 
practice, as this would take significantly more time to perform (91). Tools to detect opioid-
induced cognitive impairment in a primary care setting need to be comprehensive, easy to 
administer within a short time frame, valid and reliable (90).  
A better understanding of the cognitive domains that are affected by opioid use in this older 
adult population could lead to the use of or development of a more suitable assessment 
tool and a clearer definition of what constitutes opioid-induced cognitive impairment. 
Baldacchino and colleagues (2018) identified cognitive flexibility, cognitive impulsivity and 
verbal working memory as important cognitive domains in adults using opioids chronically.  
A more recent systematic review and meta-analysis found that long-term opioid use in 
adults reduced attention compared to other treatments that targeted the central nervous 
system (44). All studies in the current review assessed verbal working memory; with one 
detecting an improvement using the CDR micro-computerised assessment (63) and one 
finding a decline to cognitive performance using the MMSE in this domain (60). Cognitive 
flexibility was only measured in three studies and assessed with five different 
neuropsychological assessments (56, 61, 64); with only the Trail Making Task (Task B-A) 
detecting an improvement in this domain (56). Attention was also found to be affected in a 
longitudinal population-based study that screened cognition using the MMSE (60). There are 
concerns regarding the ecological validity of neuropsychological assessments, in that, there 
is a lack of agreement around the constructs that some tests aim to measure, leading to 
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difficulties in interpreting the outcome (92). This may contribute to the varied findings 
across studies. Practice effects are also a recognised characteristic from completing multiple 
assessments, where test performance may be attributed to increased familiarity (93). Out of 
the included studies that conducted multiple assessments (55-60, 62-64), two discussed 
practice effects, whilst only one study controlled for them (57). Therefore, practice effects 
may have had influence over the cognitive outcomes.  
None of the existing screening tools and neuropsychological assessments of included studies 
are suitable to evaluate all cognitive domains (94). Other domains that demonstrated 
cognitive change in the current systematic review included delayed episodic memory, 
language, orientation and psychomotor function. How we define opioid-induced cognition 
in older adults may need to consider additional cognitive domains (i.e. delayed recall/long-
term memory and psychomotor function). However, due to the methodological designs of 
the studies, small sample sizes and populations included, there could be some noise around 
cognitive effects from opioids, such as issues of pain, the disease itself and the use of 
appropriate control groups. There may also be other cognitive domains to consider that 
have not been captured in the included studies. Limited reporting of the timing of 
administration may have also hindered understanding of whether the tools and assessments 
would detect a change in cognition due to opioids (e.g. ensuring opioid plasma levels were 
at their peak) (64). 
Driving is a complex task that requires a range of cognitive skills (such as attention and 
executive functions), visuospatial skills, motor ability, and multisensory perception (95, 96). 
Previous reviews explored the impact of opioids on driving ability in adults with cancer 
and/or chronic non-cancer conditions as part of their assessment of opioid-induced 
cognitive impairment (35-38). The findings from these systematic reviews are limited due to 
the scarce number of studies available, as well as the absence of clinically relevant 
information and appropriateness of tests to assess cognition and driving ability amongst 
chronic pain populations in terms of clinical practice and everyday tasks (36, 37). Studies 
assessing driving ability were considered within the current review, however, studies were 




Clinically, opioid neurotoxicity in older adults often presents itself as sedation, confusion, as 
well as hallucinations, mood disorders and cognitive impairment (40, 42). The screening tool 
and neuropsychological assessments of included studies in this systematic review do not 
capture issues with some cognitive adverse effects, like hallucinations, and may not detect 
sedation and confusion in a clinically meaningful way. Yet, these are considered clinically 
important side effects (42, 97, 98) as well as impactful on patient wellbeing (99).  
 
Strengths and limitations  
This systematic review was guided by the PRISMA-P checklist (45, 46) to ensure that the 
protocol development and reporting were robust. Multiple search engines were searched 
(inclusive of language, publication status and publication date) to enable the identification 
of all possible literature. Another strength was our exclusion of studies where cognitive 
function may already be compromised either by existing health conditions (e.g. patients 
with dementia) or where patterns of opioid use were likely to differ (e.g. perioperative use 
or substance misuse).  
There were several potential limitations. Studies that relied on self-report or clinical opinion, 
which may be of interest in clinical practice, were not included. However, the focus on 
formal screening tools and neuropsychological assessments allowed for ease of comparison 
with previous reviews. Another limitation was defining an older adult population. We used a 
chronological age of 65 and over; as commonly adopted by most developed countries and 
for providing a suitable cut-off value for inclusion (49, 50). We recognise that some included 
participants could be less than 65 and that chronological age does not account for individual 
patient characteristics/responses to prescribed medications (100). Most included studies 
consisted of chronic non-cancer pain populations, which may limit the generalisability of 
findings to cancer pain populations. Additionally, some studies may have been 
underpowered, as they explored changes to cognition from opioid use as a secondary 
outcome. This review adopted the QualSyst tool to assess study quality, as it allowed for the 
standardised, empirically grounded, assessment of a variety of study designs (51). However, 
it lacked the ability to identify specific biases, which may have led to inflated quality grades 
of included studies.  
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Overall, the methodological issues, small sample sizes and poor reporting in the included 
studies limits how we can interpret the effects from the opioids on older adults’ cognition 
and the interpretation of the review findings. Therefore, this review does not make 
recommendations or implications for practice that go beyond the scope of the included 
evidence. 
 
Implications for practice  
This review highlights the absence of a standardised approach to assessing opioid-induced 
cognitive impairment in older adults with cancer and chronic non-cancer pain, and how 
current approaches adopted in research studies lack suitability. Therefore, the use of formal 
screening tools and neuropsychological assessments of opioid-induced cognitive 
impairment cannot replace clinical judgement and identifying clinically meaningful adverse 
effects, such as hallucinations. The use of formal screening tools should be seen as a guide 
to support clinical decisions. The MMSE does not appear to be discriminatory towards 
cognitive effects from opioid use. The use of a brief, more nuanced, screening tool that 
assesses attention, language, orientation, psychomotor function, and verbal working/short-
term and delayed episodic memory may be beneficial in practice compared to 
neuropsychological assessments in detecting opioid-induced cognitive impairment in this 
older adult population, as less time consuming to administer. However, an appropriate tool 
requires further assessment.  
 
Recommendations for future work 
This review has observed changes to some cognitive domains from opioid use in older adults 
with cancer and chronic non-cancer pain. In particular, attention, language, orientation, 
psychomotor function, and verbal working/short-term and delayed episodic memory were 
worsened. Due to the small number of primary studies available and their limitations, future 
research should focus on determining the cognitive domains affected in this older adult 
population. Future primary research studies in this area should consider adopting cognition 
as a primary objective, larger sample sizes, clearer reporting around opioid use (type, dose, 
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route of administration and length of use) and provide more detail around the 
administration of screening tools and neuropsychological assessments used. This would also 
require determining the validity and reliability of existing screening tools and 
neuropsychological assessments to detect clinically meaningful changes, and other clinically 
important adverse effects not captured by current tools and assessments. The value of 
other screening tools, other than the MMSE, to detect cognitive change from opioid use in 
older adult populations with cancer or chronic non-cancer pain requires investigation. 
 
Conclusions 
The findings of this systematic review suggest effective pain relief may be achieved at low 
daily doses, without affecting cognition. Changes to cognition (including both improvements 
and impairments) were predominantly observed in studies with higher mean opioids doses 
(120mg–190.7mg MEDD). Attention, language, orientation, psychomotor function, and 
verbal working/short-term and delayed episodic memory were worsened by opioid use. As 
neuropsychological assessments are too cumbersome for use in clinical practice, a more 
nuanced brief screening tool with consideration to the cognitive domains identified may be 
beneficial. The MMSE does not appear discriminatory enough. A better understanding of 
cognitive impairment caused by opioids in this population could be used to inform 
adjustments to pain treatment and the benefit-risk balance of opioid use.   
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Appendix 1 Example of the full search strategy 
 
Example of Ovid MEDLINE(R) Epub ahead of print, in-process & other non-indexed 
citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present search strategy: 
1. exp Analgesic, Opioid/  

















































9. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 
10. exp Cognitive Dysfunction/  
11. cognit*.mp 
12. 10 OR 11 
13. exp Aged/ 




16. Old* adult*.mp 
17. Old* age*.mp 
18. Old* Generation*.mp 
19. Old* people*.mp 
20. Senior*.mp 
21. 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 
















Table 1. Inclusion and exclusion criteria 
Study characteristic Include Exclude 
Participants Older adults aged ≥65 with cancer and/or chronic 
non-cancer pain (including an overall mean age of 
≥65, a mixed population with at least 50% aged 
≥65 or a clear subgroup analysis reporting on 
participants aged ≥65) 
Populations where substance misuse, psychiatric 
illnesses, neurocognitive/neurodegenerative 
diseases (e.g. Alzheimer’s) and brain injury are 




Studies exploring opioid use where screening 
tools and/or neuropsychological assessments 
have been used to detect opioid-induced 
cognitive impairment.  
Studies that consider recreational use and 
perioperative use of opioids, that aim to block the 
effects of opioids or that use opioids for 
antitussive relief, diarrhoea or use opioids not 
used within clinical practice.  
Studies exploring multiple medications effects on 
cognition, as long as opioids were included and a 
clear subgroup analysis was available. 
Studies that use self-report assessment or a 
healthcare professional opinion of cognitive 
function.   
Study design and 
publication type 
Randomised controlled trials, quasi-experimental 
studies and observational studies, which had 
been published in peer-review or grey literature. 
Case reports, reviews or systematic literature 
reviews, qualitative studies, opinion pieces, 
editorials, comments, news and letters. 
Publication date, 
setting (including 







Table 2. Summary of studies 
Study Design Participants recruited; including diagnosis 
and age (mean age, range and/or % of 
≥65) 
Setting Opioid type and oral 
morphine equivalent daily 










29 participants (64.5; 51.7% aged ≥65);  
Group 1: 16 healthy participants (65.4), 
Group 2: 6 advanced cancer patients not 
taking opioids (62.8) and Group 3: 7 






morphine sulphate or 
morphine sulphate solution  












154 participants with persistent 
osteoarthritis-related pain;  
Group 1: 52 participants taking Oxycodone 
(79.2), Group 2: 52 participants taking 
Codeine (77.1), Group 3: 50 participants on 
conventional therapy (77.1) 
Nursing home Immediate release 
oxycodone 32mg* 
 























60 participants with moderate to severe 














14 participants; 12 (85.7%) with cancer 





Sustained release opioid 

















57 participants with non-cancer diagnoses 
(76.1) 












Table 2. Summary of studies continued 
Study Design Sample; including diagnosis and age 
(mean age, range or % or ≥65) 
Setting Opioid type and oral 
morphine  equivalent daily 












open label)  














Slow release morphine 
47.1mg (15 – 90mg) 
Compounded slow release 














565 participants, including cancer and non-
cancer diagnoses (70.5) 
Opioid use present at baseline (N= 9), 
follow-up (N= 43) and at both time-points 


























morphine 91mg (15 – 
225mg) 
Methadone (alternative to 
morphine) 150mg 
MMSE, GPT, 
HVLT, SST  
Strong 
(0.93) 
CDR: Cognitive Drug Research (CDR) computerised assessment, D-KEFS TMT: Delis-Kaplan Executive Trail Making Test, DS: Digit Span Test, DSST: Digit Symbol 
Subtest, EC: Elevator Counting, ECD: Elevator Counting with Distraction, FT: Finger Tapping Test, GPT: Grooved Pegboard Task, GRT: Grammatical Reading 
Test, HVLT: Hopkins Verbal Learning Test, ILT: Incidental learning tests, LMT: Logical Memory Test, MMSE: Mini-Mental State Exam, MST: Map Search Test, 
NART: National Adult Reading Test, PR: Prose Recall, RT: Reaction Time, SCWT: Stroop Colour-Word Test, SST: Symbol Substitution Task (Wechsler Adult 
Intelligence Test – Revised), TMT: Trail Making Task, TST: Telephone Search Test, VFT: Verbal Fluency Test 
*Opioid combined with acetaminophen (Corsinovi et al. 2009) and naloxone (Guerriero et al. 2016). 
35 
 
Table 3. Summary of cognitive tests used in each study, cognitive domains assessed and outcomes of tests 
Study Timing of test Assessments 
and tools used 











































completed at a 
similar time 
across all visits 
from baseline 
to a maximum 




Reading Test  
 
 
The test consists of 64 sentences with 
varying levels of complexity. The test has 
been proven to be sensitive to drug effects. 
The participant is provided with a 
demonstration card, which had a written 
statement with the answer. Multiple 
practice cards (without the same answer) 
were then shown and the participant was 
asked to determine whether the statement 
was true or false. The series of cards were 
presented within 3-minutes. Scores were 
calculated using the mean time to answer 
each item and the percentage of errors. A 
different sequence of cards was used at 
each test.  
Concentration and reasoning 
 
 
No difference in the 
percentage of errors 







A fictitious news event (58 – 64 words in 
length) was presented to participants. 
Participants are asked to recall the news 
event. Each story is divided into 21 details; 
with one point awarded for each detail 
recalled word perfect or an exact synonym. 
Half points are awarded for a close 
approximation. Different passages were 
used at each test session.  
Everyday memory (Including 
short- and long-term 
memory) 
 
No difference in 
memory score and 
mean time per item 
between cancer groups*  
Authors did 
acknowledge that 
morphine group took 
slightly more time per 
item 
National Adult 
Reading Test  
 
A word-reading test to test participants’ 
capability of pronouncing 50 phonetically 
irregular words. The total number of errors 
is then tabulated. The authors acknowledge 




No difference in mean 
IQ scores between 





This test determines the effect of opioids 
on the mean reaction time by reducing 
concentration. Reduced concentration 
would result in varied response times and 
would increase the standard deviation of 
scores. This would contrast with 
participants who have ‘full’ concentration, 
since their response times should be 
narrower in range and have a reduced 
standard deviation. After each session, the 
standard deviation of all response times 
during that session was calculated.  




No difference in 





word Test  
 
 
This test measures the time taken for 
participants to read a colour word when 
printed with incongruent ink (e.g. the word 
‘Green’ printed in red). The correct 
response is to say the colour of the word 
instead of reading the word. A practice 
session of 20 items was conducted, 
followed by the test. The total time taken 
and number of errors was recorded. 
 
Selective attention and 
cognitive flexibility  
 
 
No difference in 
performance on word, 
colour or colour-word 
cards between cancer 
groups*  
Authors acknowledge 
that morphine group 









MMSE Cognitive status was assessed using the 
MMSE: lower scores were an indication of 
cognitive impairment. 
Cognitive function, including: 
attention, language, memory 
and orientation 
No difference in 
cognitive function; GLM 
between groups F= 0.1, 
p<0.877.  
GLM within groups F= 
1.3, p<0.28 
Gianni et al. 
(2011) 
Baseline and at 
follow-ups (7, 
14, 30, 60 and 
90 days) 
MMSE MMSE was used to evaluate cognitive 
impairment, whilst adjusted for age and 
education. 
Cognitive function, including: 
attention, language, memory 
and orientation 





et al. (2016) 
Baseline and 
week 52 
MMSE Cognitive state was assessed with normal 
cognition being scored as >25.  
Cognitive function, including: 
attention, language, memory 
and orientation 






































Digit Span Participants forwards and backwards digit 
span was assessed in a standard format.  
Attention and working 
memory 
No difference between 
forward digit span 
(Placebo: 6.2±1.2 and 
Morphine 6.0±0.8) in 
forward digit span or 
backward digit span 
(Placebo: 3.6±1.1 and 
Morphine: 4.0±1.0) 
Finger Tapping Participants were asked to press a 
computer keyboard space bar with their 
dominant hand using their index finger as 
quickly as possible for 1 minute. The score 
was the number of taps recorded. 
Psychomotor sedation No difference in tapping 
rate between placebo 
(267.1 ± 44.6) and 




















Four versions of the prose recall were used. 
Participants listened to a news story (prose 
passage) and were asked to recall the 
passage immediately, pre- and post- 
treatment. Later in the post-treatment 
session, participants were asked for 
delayed recall of the news stories from pre-
treatment and post-treatment. The delay 
between immediate and delayed recall was 
65 minutes for the pre-treatment story and 
20 minutes for the post-treatment story. 
Standard scoring was used, with 1 point for 
every correctly recalled ‘idea unit’ or exact 
synonym. Half points were awarded for 
partial recall or synonym. Previous research 
demonstrated sensitivity to opioid-induced 
recall impairments (101). 
Immediate and delayed 
episodic memory 
Decline in immediate 
recall following 
morphine but no main 
effect of treatment 
(F(1,13)=4.366, P=0.057) 
 
Decline in delayed recall 
for prose passages 
before and after 
morphine, significant 























































units recalled after 
placebo and 4.2±2.8 
after morphine 
(F(1,13)=13.01, P=0.003  
 
Recall of pre-treatment 
story was reduced 
following morphine 
(4.7±2.0 idea units) 
compared to placebo 
6.1±2.5 idea units 














A timed tracking task that consists of two 
parts. Part A comprises of joining 
numbered circles (1-25) and Part B requires 
participants to join alternating numbers (1-
13) and alphabetised circles (A-L). Mistakes 
would be highlighted to participants but 
the timing would be continuous. Sample 
sheets were provided for both parts to 
ensure that the participant understood the 
task. A difference score is produced by 
subtracting A from B, which produces a 
score that highly correlates with mental 
ability tests. 
Attention, psychomotor 
speed and cognitive 
flexibility 
 
(Part A & B: psychomotor 
performance, Part B: 
attention and B-A: cognitive 
flexibility) 
Improved performance 
on part A following 
morphine compared 
with placebo (Z=2.13, 
P=0.033). On part B 
those on morphine were 
slower (Z= 2.12, P= 
0.034).  
Set shifting and 
conceptual flexibility 
(time to complete trails 
B – trails A) was 
increased following 
morphine (Z= 2.28, P= 
0.023 






Participants were asked to generate as 
many words as possible in one minute with 
a particular letter (e.g. B or M) to assess 
phonemic fluency, avoiding proper nouns 
and inflections of the same word. Semantic 
Phonemic fluency and 
semantic fluency 
(Cognitive flexibility) 
No significant effects of 
treatment for phonemic 
fluency (10.1±5.0 words 
following placebo; 
9.5±3.3 following 


































 fluency was assessed using categories of 
fruit and vegetables.   
fluency (10.6±4.7 words 
following placebo; 9.5 
following morphine) 
Tests of Everyday Attention  
Elevator 
Counting 
Participants are asked to imagine 
themselves in an elevator where they do 
not have a visual floor-indicator. They were 
asked to count tones (played on a tape 
recorder) to determine which floor they 
would be on. Seven sets of tone sequences 
were to be counted, varying from three to 
fourteen tones within one series. A score of 
7 (one point per series correctly counted) 
indicated a ‘normal’ performance, whereas 
6 indicated ‘possible abnormality’ and 5 
indicates ‘abnormality’.  
Auditory sustained attention No difference in 
performance between 
placebo (6.5±0.5) and 




This task requires participants to count low 
frequency tones while ignoring high 
frequency tones. A series of low and high 
frequency tones containing between two 
and fourteen target low tones is played. 
Participants are awarded a point for each 
series when the correct number of low 
tones was counted. 
Auditory selective attention No difference in 
performance between 
placebo (7.2±2.5) and 
morphine (9.3±8.2) 
groups 
Map Search A time-limited task that requires 
participants to search for and mark symbols 
on a map of Philadelphia within two 
minutes.   
Selective visual attention No difference between 
placebo (37.6±16.9) and 
morphine (36.9±14.8) in 







This is a timed visual task. Participants are 
asked to imagine that they are in 
Philadelphia and need to find a plumber or 
a restaurant. They are asked to scan the 
‘yellow pages’ directory for plumbers or 
Selective attention No difference between 
placebo (4.8±1.0) and 
morphine (5.1±1.4) in 







restaurants and place a mark on entries 
that had the same symbols (e.g. two stars 
or two circles). Participants are asked to 
work as quickly and accurately as possible 
and to not check their responses. The time 
taken to complete the search and number 
of correctly marked targets are recorded 
(false positives were ignored). The number 
of targets divided by the time taken to 
complete the task to create the dependent 
variable (time per target). 
Karp et al. 
(2006) 
Not reported MMSE Cognitive function was assessed to 
determine participant eligibility. All 
subjects were required to have a Mini 







Making Test  
Mental flexibility was assessed with the 
Trail Making Test of the Delis-Kaplan 
Executive Function System (D-KEFS). This 
test is similar to the traditional Trail Making 
Test, but is comprised of five subtests that 
may be used to correct for processes other 
than mental flexibility that may be 
contributing to a slow response time or to 
set-shifting errors. These tests are also age-
adjusted. The D-KEFS Trail Making subtests 
administered to patients include the 
number-letter switching condition (similar 
to the traditional Trails B) that is a measure 
of mental flexibility. The other is a test of 
motor speed (similar to the traditional 
Trails A). 
 
Mental flexibility (cognitive 
flexibility) and psychomotor 
speed  
No difference between 
opioid users (7.7±3.9) 
and non-opioid users 
(9.3±4.4) in mental 
flexibility (number-letter 
switching), t=1.38, df= 
50, p= 0.17   
 
No difference between 
opioid users (9.9±3.5) 
and non-opioid users 
(10.7±3.4) in 
psychomotor speed, t= 
0.81, df= 50, p= 0.42 
 











Highly sensitive to neuropsychological 
dysfunction (31) and is another probe of 
mental flexibility. This visuoperceptual 
decoding task requires the subject to 
associate single-digit numbers with 
unfamiliar symbols. A stimulus set of nine 
printed digit-symbol pairs is presented 
above rows of numbers without the 
appropriate symbols. The subject is 
instructed to draw the correct symbol 
below each of the numbers using the digit-
symbol code presented above. The score is 
based on the number of substitutions 
completed within 90-seconds. 
Cognitive flexibility (referred 
to as mental flexibility) 
No difference between 
opioid users (10.9±3.0) 
and non-opioid users 
(11.7±2.8), t=0.91, 
df=49, p= 0.37 
 





Memory was assessed with the incidental 
learning tests administered immediately 
following the DSST. Paired-recall involves 
completing a number of Digit Symbol items 
without access to the code key; free recall, 
simply reproducing the symbols from 
memory. These tests of memory were only 
administered if patients completed four 
rows of the DSST test within 120 seconds. 
The reason for this was to standardize the 
time each patient was exposed to the 
digit/symbol stimuli.  
Memory (including free 
recall and paired recall 
Unprompted memory 
was worse in opioid 
users (6.3±1.1) 
compared to non-opioid 
users (7.0±1.1) in the 
free recall test, t= 2.17, 
df= 39, p=0.04 
 
No difference in paired 
recall between the 
opioid users (6.9±4.2) 
and non-opioid users 
(7.7±5.1), t= 0.56, df= 
39, p= 0.58 
 
Reduced number (20 
opioid users/21 non-




























Day 14 (last 
recorded 
assessment - 
used as the last 
value when 
data were 




























A series of tests were used, including: 
simple reaction time, choice reaction time, 
digit vigilance, memory scanning, 
immediate and delayed word recall, word 
recognition, picture recognition and critical 
flicker fusion threshold. Tasks are 
presented on a microcomputer and 
participants responded using one of two 
buttons within a single box. For a further 





Power of Concentration 
(Ability to attend to change 
or concentrate for sustained 
periods of time) 
No significant difference 
between baseline (1654 
(1484, 1825)) and last 
recorded visit in ability 
to concentrate (1623 
(1469, 1776), P= 0.6771) 
Quality of concentration 
(Accuracy and speed of 
concentration, combined) 
No significant difference 
between baseline (89.3 
(86.8, 91.7)) and last 
recorded visit in 
accuracy and speed of 
concentration (89.2 
(85.6, 92.9), P= 0.8341) 
Quality of working memory 
(Ability to retain and retrieve 
information in short-term 
memory) 
Significant improvement 
in quality of working 
memory between 
baseline (1.5 (1.3, 1.8)) 
and last recorded visit 
(1.7 (1.6, 1.8), P= 
0.0345) 
Quality of secondary 
memory (Ability to retain 
and retrieve information in 
long-term memory)  
No significant difference 
between baseline (207 
(188, 226)) and last 
recorded visit in ability 
to retrieve information 
from long-term memory 
(192 (167, 217), P= 
0.3218)  
Speed of memory (Speed of 
information retrieval) 
Significant improvement 
in speed of memory 
from baseline (5551 
(4583, 6519)) and last 
recorded visit 4878 




et al. (1994) 
Baseline and 2-
months 
MMSE Cognition was assessed using the Mini-
Mental Status Exam. 
Cognitive function, including: 
attention, language, memory 
and orientation 
No difference in 








both phase 1 
and phase 2  
MMSE The test comprises of 23-items, and the 
sum of scores ranges from 0 to 30. Higher 
scores indicate better cognitive 
performance. The mean change in MMSE 
sum scores during follow-up was used as an 
outcome variable.  
Cognitive function, including: 
attention, language, memory 
and orientation 
MMSE scores of opioid 
users were significantly 
worse than the group 
(no medications with 
effects to CNS) (P= 
0.032) 
MMSE scores of opioid 
users were significantly 
worse than the control 
group (non-users of 
corresponding 
medications) (P= 0.021) 
The combination of 
opioids and other CNS 
medications was also 
associated with 
cognitive decline (P= 
0.007) 



















phase), with 3 
treatment 
periods (opioid, 
MMSE Cognitive function was assessed to 




No description provided. Concentration and 
psychomotor function 
No difference in 
performance* 







The test comprises a 12-item word list, 
which is composed of four words from 
three semantic categories. Participants 
read the word list and aim to memorise the 
words. The word list is then read to the 
participant at a rate of 2 seconds per word. 



























The participant’s free recall of the list is 
recorded. This is repeated for two more 
trials. At the end of the third trial, the 
participant is read 24 words and is asked 
comment ‘yes’ for words that appeared on 
the recall list (12 targets) and ‘no’ for words 
that did no (12 distractors). Half of the 
distractors are from the same semantic 
category as the targets (related 
distractors), whilst half are drawn from 
other categories (unrelated distractors). 
There are 6 forms of the test and requires 






Test – Revised) 
No description provided. Manual dexterity and 
psychomotor speed 
No difference in 
performance* 
GLM: General Linear Model, MMSE: Mini-Mental State Exam 
* Clemons et al. (1996): Statistical significance between advanced cancer groups was not reported, inferences based on author description and mean trends. 
Gianni et al. (2011): P value not provided but authors note the outcome is not statistically significant. Guerriero et al. (2016): Statistical significance is not 
reported but mean MMSE score from baseline to endpoint provided in graph, authors acknowledge MMSE score remained stable across time-points. Raja et 









Table 4. A summary of opioids used across included studies and oral morphine equivalent conversion 
Study Opioid type, route of administration and 
length of use 
Reported opioid dose 
(Mean dose and/or range) 
Oral morphine equivalent 
daily dose (MEDD; Mean 
and/or range) 
Average MEDD 
(Mean and/or range) 




Type: Controlled-release morphine sulphate 
or morphine sulphate solution  
Route: Oral 
Length of use: No exact date of 
commencement for 5/7 participants. Earliest 




104.3mg/d (50 – 200mg) 
 
 
104.3mg (50 – 200mg)  
 
 
104.3mg (50 – 
200mg) 




Type: Immediate release oral oxycodone 
Route: Oral  
Length of use: 6 weeks 
Baseline: 5mg/12h 
 
Average daily dose: 10 – 
20mg/d 
 
Average dose at end of 
study: 16mg/d  
Baseline: 20mg 
 
Average daily dose: 20 – 
40mg 
 







Type: Immediate release codeine 
Route: Oral 
Length of use: 6 weeks 
Baseline: 30mg/8h 
 
Average daily dose: 90 – 
120mg/d 
 




Average daily dose: 9 – 
12mg 
 













Length of use: 3 months 
End of 3-month 
observation 
 
11.7 µg/h in 3.5%;  
17.5 µg/h in 11.6%;  
35 µg/h in 74.4%;  
52.5 µg/h in 9.3%;  
70 µg/h in 1.2%.  
End of 3-month observation 
 
 
20 – 31.7mg/d in 3.5% 
30 – 47.5mg/d in 11.6% 
60 – 95mg/d in 74.4% 
95 – 145mg/d in 9.3% 




60 - 95mg 
46 
 
Study Opioid type, route of administration and 
length of use 
Reported opioid dose 
(Mean dose and/or range) 
Oral morphine equivalent 
daily dose (MEDD; Mean 
and/or range) 
Average MEDD 




Type: Oxycodone prolonged release 
Route: Oral 
Length of use: 52 weeks 
Baseline: 10mg/d 
 
Week 4: 14.4mg/d ± 
4.9mg/d  
 
Week 52: 17.4mg/d ± 
7.7mg/d  
 
During follow-up, the daily 
dose increased to 20mg/d 
in 42% of patients at 4 
weeks and to 40mg/d at 52 




Week 4: 28.8mg ± 9.8mg 
 
 
Week 52: 34.8mg ± 15.4mg 
 
 
During follow-up, the daily 
dose increased to 40mg/d in 
42% of patients at 4 weeks 
and to 80mg/d at 52 weeks 







34.8mg ± 15.4mg 
 




Type: Sustained release morphine  
Route: Oral (50%), transdermal patch (42.9%) 
and syringe driver (7.1%)  
Length of use: 11.7 days (SD: 4.7 days) 




190.7mg ± 266.6 mg (30 – 
800 mg) 
 
190.7mg ± 266.6 mg 
(30 – 800 mg) 
 
Type: Immediate release morphine 
Route: Oral 
Length of use: Mean: 11.7 days (SD: 4.7 days) 
21.4mg/d ± 25.6mg/d (5 – 
100mg/d) 
 
21.4mg ± 25.6mg (5 – 
100mg) 
 
21.4mg ± 25.6mg (5 – 
100mg) 
 
Karp et al. 
(2006) 
Not reported Not reported Not reported Not reported 
McNamara et 




Length of use: 14 days 
Baseline: 25µg/h or 50µg/h 
 
 
Maintenance dose of 
50µg/h – 100µg/h (25µg/h 
– 450µg/h). 
Baseline 60mg – 90mg or 
120mg – 190mg 
 
Maintenance dose of 120mg 
– 240mg (60mg – 1080mg) 
 
 
120mg – 240mg 
(60mg – 1080mg) 
47 
 
Study Opioid type, route of administration and 
length of use 
Reported opioid dose 
(Mean dose and/or range) 
Oral morphine equivalent 
daily dose (MEDD; Mean 
and/or range) 
Average MEDD 






Type: Slow release morphine 
Route: Oral 
Length of use: Mean: 11.86 months (3 – 20 
months) 
47.1mg/d (15mg/d - 
90mg/d) 
 






Type: Compounded slow release oxycodone 
Route: Oral 
Length of use: Mean: 7 months 
27.5mg/d (7.5mg/d – 
45mg/d) 
 















Type: Codeine, dextropropoxyphene, 
ethylmorphine and dextromethorphan 
Route: Not reported 
Length of use: Not clearly reported 
(Dichotomised into regular and irregular use)  
 










Type: Controlled-release morphine 
Route: Not reported 
Length of use: 8 weeks 
91mg/d (15mg/d to 225 
mg/d) 
91mg (15mg to 225 mg) 91mg (15mg - 225 
mg) 
Type: Methadone (Alternative to morphine) 
Route: Not reported 
Length of use: 8 weeks 









searching (n= 5,086) 
Records identified through handsearching first 
author’s EndNote library, relevant journal 
indexes and systematic reviews reference lists, 
and reference list and citation searching of 
included studies (n= 788) 
Records after duplicates 













Records screened  
(n= 4,036) 
Records excluded after title and 
abstract review  
(n= 3,979) 
Full-text articles assessed 
for eligibility (n= 57) 
Full-text articles excluded,  
with reasons (n= 47) 
29 with a mean age <65, a mixed 
population with <50% aged ≥65 
or no subgroup analysis on 
participants aged ≥65 
2 with a presence neurocognitive 
and neurodegenerative diseases 
2 without screening tools/ 
neuropsychological assessment 
or used self-report 
9 No response from author for 
further information or full-text 
access 
1 Authors unable to provide 
necessary data 
4 lacked focus on the effect of 
opioids on cognition or did not 
have a subgroup analysis 
Studies included in 















Figure 2. Impact of opioids on cognition, mapped by cognitive domain 
 
Opioids; (B): Buprenorphine, (C): Codeine, (D): Dextropropoxyphene, (De): Dextromethorphan, (E): Ethylmorphine, (F): Fentanyl, (H): Hydromorphone, (O): 
Oxycodone; (Me): Methadone, (Mo): Morphine, IR: Immediate release, SR: Sustained release. 
Screening tools and neuropsychological tests; CDR: Cognitive Drug Research computerised assessment, D-KEFS TMT: Delis-Kaplan Executive Trail Making 
Test, DS: Digit Span, DSST: Digit Symbol Subtest, FT: Finger Tapping, GPT: Grooved Pegboard Task, GRT: Grammatical Reading Test, HVLT: Hopkins Verbal 
Learning Test, ILT: Incidental Learning Test (including free recall and paired recall), LMT: Logical Memory Test, MMSE: Mini-mental State Examination, 
NART: National Adult Reading Test, PR: Prose Recall, RT: Reaction Time, SCWT: Stroop Colour-Word Test, SST: Symbol Substitution Task, TEA: Tests of 
Everyday Attention, TMT(A): Trail Making Test (Part A), TMT(B): Trail Making Test (Part B), TMT(B-A): Trail Making Test (Part B – Part A), VFT: Verbal Fluency 
Test. 
a Cognitive domain from Baldacchino et al. 2012 
* No significant change to cognition but authors acknowledged a trend towards a decline in performance 
